Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Regenerative Medicine | 30 | 2019 | 187 | 9.080 |
Why?
|
Tissue Engineering | 40 | 2020 | 608 | 7.140 |
Why?
|
Kidney Transplantation | 35 | 2020 | 352 | 6.550 |
Why?
|
Tissue Scaffolds | 32 | 2020 | 386 | 5.780 |
Why?
|
Extracellular Matrix | 22 | 2020 | 226 | 5.220 |
Why?
|
Organ Transplantation | 15 | 2019 | 65 | 4.760 |
Why?
|
Liver Transplantation | 29 | 2015 | 111 | 4.160 |
Why?
|
Kidney | 17 | 2020 | 486 | 3.930 |
Why?
|
Regeneration | 16 | 2019 | 167 | 3.280 |
Why?
|
Bioengineering | 14 | 2017 | 67 | 3.230 |
Why?
|
Graft Rejection | 14 | 2018 | 149 | 3.230 |
Why?
|
Immunosuppression | 15 | 2016 | 80 | 2.820 |
Why?
|
Graft Survival | 20 | 2020 | 228 | 2.450 |
Why?
|
Humans | 118 | 2020 | 29147 | 1.930 |
Why?
|
Pancreas | 6 | 2020 | 79 | 1.910 |
Why?
|
Immune Tolerance | 8 | 2018 | 67 | 1.880 |
Why?
|
Stem Cell Transplantation | 9 | 2019 | 203 | 1.860 |
Why?
|
Immunosuppressive Agents | 15 | 2015 | 167 | 1.820 |
Why?
|
Biocompatible Materials | 9 | 2018 | 210 | 1.660 |
Why?
|
Tissue Donors | 12 | 2018 | 167 | 1.630 |
Why?
|
Pancreas Transplantation | 8 | 2018 | 80 | 1.420 |
Why?
|
Animals | 44 | 2018 | 7300 | 1.350 |
Why?
|
Kidney Diseases | 4 | 2015 | 239 | 1.250 |
Why?
|
Postoperative Complications | 9 | 2018 | 670 | 1.240 |
Why?
|
Stem Cells | 10 | 2019 | 292 | 1.240 |
Why?
|
Kidney Failure, Chronic | 8 | 2018 | 518 | 1.210 |
Why?
|
Gastrointestinal Diseases | 3 | 2018 | 38 | 1.150 |
Why?
|
Transplantation Immunology | 6 | 2017 | 27 | 1.070 |
Why?
|
Insulin-Secreting Cells | 4 | 2020 | 53 | 0.970 |
Why?
|
Liver Failure | 5 | 2013 | 17 | 0.940 |
Why?
|
Islets of Langerhans Transplantation | 6 | 2018 | 40 | 0.920 |
Why?
|
Liver Neoplasms | 5 | 2013 | 162 | 0.890 |
Why?
|
Liver | 8 | 2015 | 464 | 0.840 |
Why?
|
Islets of Langerhans | 6 | 2020 | 74 | 0.830 |
Why?
|
Renal Artery | 3 | 2018 | 43 | 0.800 |
Why?
|
Gastrointestinal Tract | 4 | 2016 | 29 | 0.780 |
Why?
|
Adult | 35 | 2020 | 8441 | 0.760 |
Why?
|
Gene Expression Profiling | 2 | 2020 | 320 | 0.730 |
Why?
|
Male | 48 | 2020 | 17832 | 0.710 |
Why?
|
Tissue and Organ Procurement | 6 | 2018 | 69 | 0.710 |
Why?
|
RNA | 1 | 2020 | 88 | 0.700 |
Why?
|
Delayed Graft Function | 6 | 2020 | 33 | 0.690 |
Why?
|
Bioartificial Organs | 3 | 2014 | 25 | 0.680 |
Why?
|
Diabetes Mellitus, Type 1 | 3 | 2018 | 180 | 0.670 |
Why?
|
Eubacterium | 2 | 2008 | 2 | 0.640 |
Why?
|
Cold Ischemia | 1 | 2018 | 7 | 0.640 |
Why?
|
Gram-Positive Bacterial Infections | 2 | 2008 | 9 | 0.640 |
Why?
|
Hepatectomy | 2 | 2008 | 66 | 0.630 |
Why?
|
Middle Aged | 33 | 2020 | 10846 | 0.620 |
Why?
|
Female | 44 | 2020 | 18189 | 0.600 |
Why?
|
Glycosaminoglycans | 1 | 2016 | 20 | 0.590 |
Why?
|
Transplantation Tolerance | 3 | 2011 | 14 | 0.570 |
Why?
|
Cells, Cultured | 5 | 2019 | 799 | 0.550 |
Why?
|
Intercellular Signaling Peptides and Proteins | 2 | 2017 | 100 | 0.550 |
Why?
|
Microvessels | 1 | 2015 | 23 | 0.540 |
Why?
|
Mycophenolic Acid | 3 | 2015 | 28 | 0.530 |
Why?
|
Kidney Glomerulus | 1 | 2015 | 30 | 0.530 |
Why?
|
Cephalosporins | 1 | 2014 | 7 | 0.510 |
Why?
|
Hemodynamics | 1 | 2015 | 148 | 0.510 |
Why?
|
Antibiotic Prophylaxis | 1 | 2014 | 29 | 0.500 |
Why?
|
Hepatitis C | 3 | 2011 | 38 | 0.490 |
Why?
|
Facial Transplantation | 3 | 2018 | 8 | 0.480 |
Why?
|
Isoantibodies | 1 | 2014 | 10 | 0.480 |
Why?
|
Bioprosthesis | 1 | 2014 | 55 | 0.470 |
Why?
|
Follow-Up Studies | 14 | 2019 | 2111 | 0.460 |
Why?
|
Hemangiosarcoma | 1 | 2013 | 8 | 0.460 |
Why?
|
Spinal Fusion | 3 | 2018 | 42 | 0.450 |
Why?
|
Gastroenterology | 1 | 2012 | 2 | 0.450 |
Why?
|
Radiography, Interventional | 2 | 2014 | 35 | 0.450 |
Why?
|
Retrospective Studies | 17 | 2019 | 3112 | 0.440 |
Why?
|
Abdomen | 1 | 2012 | 42 | 0.430 |
Why?
|
Donor Selection | 4 | 2019 | 31 | 0.430 |
Why?
|
Anti-Bacterial Agents | 1 | 2014 | 285 | 0.420 |
Why?
|
General Surgery | 1 | 2012 | 81 | 0.400 |
Why?
|
Time Factors | 15 | 2017 | 2001 | 0.390 |
Why?
|
Telangiectasia, Hereditary Hemorrhagic | 2 | 2007 | 2 | 0.390 |
Why?
|
Treatment Outcome | 17 | 2018 | 3105 | 0.380 |
Why?
|
Clinical Protocols | 1 | 2010 | 95 | 0.380 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2014 | 271 | 0.380 |
Why?
|
Scrotum | 1 | 2010 | 8 | 0.370 |
Why?
|
Hernia | 1 | 2010 | 12 | 0.370 |
Why?
|
Ureteral Diseases | 1 | 2010 | 7 | 0.370 |
Why?
|
Hemorrhage | 2 | 2013 | 91 | 0.370 |
Why?
|
Thoracic Vertebrae | 3 | 2018 | 42 | 0.350 |
Why?
|
Biopsy, Needle | 2 | 2012 | 89 | 0.340 |
Why?
|
Bone Marrow Transplantation | 2 | 2009 | 65 | 0.330 |
Why?
|
Carcinoid Tumor | 1 | 2008 | 22 | 0.330 |
Why?
|
Recurrence | 7 | 2014 | 235 | 0.330 |
Why?
|
Pregnancy Complications | 3 | 2015 | 80 | 0.330 |
Why?
|
Aneurysm | 1 | 2008 | 21 | 0.330 |
Why?
|
Hemothorax | 1 | 2008 | 6 | 0.330 |
Why?
|
Urinary Tract | 1 | 2008 | 21 | 0.330 |
Why?
|
Diabetes Mellitus | 3 | 2018 | 368 | 0.330 |
Why?
|
Cadaver | 6 | 2018 | 143 | 0.330 |
Why?
|
Liver Diseases | 3 | 2018 | 61 | 0.320 |
Why?
|
Pleural Effusion | 1 | 2008 | 12 | 0.320 |
Why?
|
Ureter | 1 | 2008 | 35 | 0.320 |
Why?
|
Kidney Pelvis | 1 | 2008 | 21 | 0.320 |
Why?
|
Opportunistic Infections | 1 | 2007 | 9 | 0.320 |
Why?
|
Sirolimus | 3 | 2013 | 35 | 0.310 |
Why?
|
Fever | 1 | 2008 | 56 | 0.310 |
Why?
|
Prognosis | 7 | 2018 | 1362 | 0.310 |
Why?
|
Scoliosis | 2 | 2017 | 23 | 0.310 |
Why?
|
Bioreactors | 4 | 2018 | 59 | 0.300 |
Why?
|
Swine | 7 | 2018 | 201 | 0.300 |
Why?
|
Tissue Transplantation | 2 | 2018 | 16 | 0.290 |
Why?
|
Intestine, Small | 3 | 2017 | 34 | 0.290 |
Why?
|
Transplantation, Homologous | 3 | 2017 | 113 | 0.290 |
Why?
|
Cell Differentiation | 4 | 2018 | 436 | 0.290 |
Why?
|
Reconstructive Surgical Procedures | 1 | 2008 | 190 | 0.280 |
Why?
|
Perfusion | 5 | 2019 | 64 | 0.280 |
Why?
|
Dyslipidemias | 1 | 2007 | 52 | 0.280 |
Why?
|
Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2005 | 3 | 0.280 |
Why?
|
Tacrolimus | 3 | 2014 | 44 | 0.280 |
Why?
|
Hypertension, Portal | 1 | 2005 | 9 | 0.280 |
Why?
|
Survival Rate | 6 | 2018 | 795 | 0.270 |
Why?
|
Organ Culture Techniques | 4 | 2017 | 38 | 0.270 |
Why?
|
Organogenesis | 2 | 2016 | 15 | 0.270 |
Why?
|
Vagina | 1 | 2005 | 47 | 0.270 |
Why?
|
Forecasting | 2 | 2017 | 133 | 0.270 |
Why?
|
Quality of Life | 5 | 2015 | 817 | 0.260 |
Why?
|
Myocytes, Smooth Muscle | 2 | 2015 | 74 | 0.260 |
Why?
|
Graft vs Host Disease | 1 | 2005 | 18 | 0.260 |
Why?
|
Risk Factors | 8 | 2018 | 3537 | 0.250 |
Why?
|
Cholangitis | 1 | 2004 | 2 | 0.250 |
Why?
|
Biliary Tract Surgical Procedures | 1 | 2004 | 7 | 0.250 |
Why?
|
Portal Vein | 3 | 2013 | 16 | 0.240 |
Why?
|
History, 20th Century | 3 | 2018 | 68 | 0.240 |
Why?
|
Aged | 18 | 2019 | 9494 | 0.240 |
Why?
|
Hypertension | 2 | 2009 | 910 | 0.230 |
Why?
|
Keratins | 2 | 2013 | 36 | 0.230 |
Why?
|
Biopsy | 6 | 2014 | 241 | 0.230 |
Why?
|
Transplants | 2 | 2014 | 22 | 0.220 |
Why?
|
Kidney Function Tests | 3 | 2018 | 102 | 0.220 |
Why?
|
Registries | 4 | 2016 | 278 | 0.220 |
Why?
|
Pancreatic Pseudocyst | 1 | 2002 | 4 | 0.220 |
Why?
|
Liver Regeneration | 2 | 2012 | 23 | 0.220 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2011 | 1379 | 0.210 |
Why?
|
Glomerular Filtration Rate | 3 | 2018 | 287 | 0.210 |
Why?
|
Thrombosis | 1 | 2002 | 60 | 0.210 |
Why?
|
Ear | 2 | 2018 | 18 | 0.200 |
Why?
|
Rats | 8 | 2018 | 1604 | 0.200 |
Why?
|
Intestines | 2 | 2012 | 54 | 0.200 |
Why?
|
Solubility | 1 | 2020 | 38 | 0.190 |
Why?
|
Immunohistochemistry | 4 | 2017 | 519 | 0.190 |
Why?
|
Microscopy, Electron, Scanning | 3 | 2015 | 92 | 0.190 |
Why?
|
Disease Progression | 6 | 2017 | 572 | 0.190 |
Why?
|
Cyclosporine | 3 | 2011 | 34 | 0.190 |
Why?
|
Europe | 4 | 2016 | 77 | 0.190 |
Why?
|
Transplantation, Autologous | 2 | 2017 | 78 | 0.190 |
Why?
|
Radiography | 2 | 2017 | 353 | 0.180 |
Why?
|
Young Adult | 9 | 2019 | 2406 | 0.180 |
Why?
|
Adolescent | 7 | 2019 | 3257 | 0.180 |
Why?
|
Death, Sudden, Cardiac | 1 | 2020 | 59 | 0.180 |
Why?
|
Polycystic Kidney, Autosomal Dominant | 2 | 2012 | 10 | 0.170 |
Why?
|
Pylorus | 2 | 2015 | 5 | 0.170 |
Why?
|
Allergy and Immunology | 1 | 2019 | 3 | 0.170 |
Why?
|
Sterilization | 1 | 2018 | 2 | 0.170 |
Why?
|
Powders | 1 | 2018 | 8 | 0.170 |
Why?
|
Child | 4 | 2019 | 2219 | 0.170 |
Why?
|
Neovascularization, Physiologic | 3 | 2014 | 106 | 0.170 |
Why?
|
Endarterectomy | 1 | 2018 | 7 | 0.160 |
Why?
|
Child, Preschool | 4 | 2019 | 1167 | 0.160 |
Why?
|
Muscle, Smooth | 2 | 2015 | 73 | 0.160 |
Why?
|
Omentum | 2 | 2017 | 26 | 0.160 |
Why?
|
Kyphosis | 1 | 2018 | 10 | 0.160 |
Why?
|
Risk Assessment | 4 | 2015 | 1306 | 0.160 |
Why?
|
Mesenchymal Stem Cell Transplantation | 2 | 2019 | 75 | 0.160 |
Why?
|
Alginates | 2 | 2017 | 49 | 0.160 |
Why?
|
Diabetes Mellitus, Experimental | 2 | 2017 | 51 | 0.150 |
Why?
|
Infant | 3 | 2019 | 969 | 0.150 |
Why?
|
Liver Cirrhosis | 3 | 2012 | 75 | 0.150 |
Why?
|
Pressure | 2 | 2016 | 54 | 0.150 |
Why?
|
Osteotomy | 1 | 2018 | 49 | 0.150 |
Why?
|
Insulin | 2 | 2016 | 346 | 0.150 |
Why?
|
Collagen | 3 | 2014 | 217 | 0.150 |
Why?
|
Osmotic Pressure | 1 | 2017 | 9 | 0.150 |
Why?
|
Implants, Experimental | 1 | 2016 | 12 | 0.150 |
Why?
|
Immunomodulation | 1 | 2017 | 30 | 0.150 |
Why?
|
Esophagogastric Junction | 1 | 2016 | 7 | 0.150 |
Why?
|
Imaging, Three-Dimensional | 1 | 2017 | 130 | 0.150 |
Why?
|
Nephrectomy | 2 | 2016 | 114 | 0.150 |
Why?
|
Cell Proliferation | 2 | 2016 | 573 | 0.150 |
Why?
|
Macrophage Activation | 1 | 2016 | 9 | 0.150 |
Why?
|
Apolipoproteins | 2 | 2016 | 196 | 0.150 |
Why?
|
Living Donors | 2 | 2015 | 54 | 0.150 |
Why?
|
Cells, Immobilized | 1 | 2017 | 23 | 0.150 |
Why?
|
Nephritis, Hereditary | 1 | 2016 | 3 | 0.150 |
Why?
|
Hemostasis | 2 | 2013 | 5 | 0.140 |
Why?
|
Prospective Studies | 5 | 2018 | 2021 | 0.140 |
Why?
|
Lipoproteins, HDL | 2 | 2016 | 247 | 0.140 |
Why?
|
Cell Separation | 1 | 2017 | 86 | 0.140 |
Why?
|
Hemangioendothelioma, Epithelioid | 2 | 2007 | 3 | 0.140 |
Why?
|
Immunocompetence | 2 | 2014 | 12 | 0.140 |
Why?
|
Survival Analysis | 3 | 2019 | 440 | 0.140 |
Why?
|
Antigens, Differentiation | 1 | 2015 | 21 | 0.140 |
Why?
|
History, 21st Century | 2 | 2018 | 48 | 0.140 |
Why?
|
Antibodies, Antiphospholipid | 1 | 2015 | 1 | 0.140 |
Why?
|
Antiphospholipid Syndrome | 1 | 2015 | 4 | 0.140 |
Why?
|
Protein Array Analysis | 1 | 2015 | 16 | 0.140 |
Why?
|
Corrosion Casting | 1 | 2015 | 9 | 0.140 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2015 | 20 | 0.140 |
Why?
|
Enteric Nervous System | 1 | 2015 | 2 | 0.130 |
Why?
|
Chitosan | 1 | 2015 | 3 | 0.130 |
Why?
|
Caveolin 1 | 1 | 2015 | 13 | 0.130 |
Why?
|
Uremia | 1 | 2015 | 9 | 0.130 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2015 | 103 | 0.130 |
Why?
|
Lung | 2 | 2015 | 233 | 0.130 |
Why?
|
Health Services Accessibility | 1 | 2017 | 231 | 0.130 |
Why?
|
C-Peptide | 1 | 2014 | 25 | 0.130 |
Why?
|
Macrophages | 1 | 2016 | 188 | 0.130 |
Why?
|
Mice | 4 | 2017 | 2371 | 0.130 |
Why?
|
Transplantation Conditioning | 1 | 2014 | 11 | 0.130 |
Why?
|
Fibrosis | 2 | 2014 | 103 | 0.130 |
Why?
|
Antilymphocyte Serum | 1 | 2014 | 17 | 0.130 |
Why?
|
Steroids | 1 | 2014 | 36 | 0.130 |
Why?
|
Ossification, Heterotopic | 1 | 2014 | 14 | 0.120 |
Why?
|
Polyglycolic Acid | 1 | 2014 | 32 | 0.120 |
Why?
|
Perioperative Care | 1 | 2014 | 58 | 0.120 |
Why?
|
Age Factors | 5 | 2019 | 1108 | 0.120 |
Why?
|
Muscles | 1 | 2014 | 53 | 0.120 |
Why?
|
Embolization, Therapeutic | 1 | 2014 | 79 | 0.120 |
Why?
|
Heart | 2 | 2015 | 162 | 0.120 |
Why?
|
Cell-Free System | 2 | 2015 | 15 | 0.120 |
Why?
|
Guided Tissue Regeneration | 1 | 2014 | 36 | 0.120 |
Why?
|
Waiting Lists | 1 | 2013 | 30 | 0.120 |
Why?
|
Drainage | 1 | 2013 | 49 | 0.120 |
Why?
|
Regional Blood Flow | 1 | 2013 | 82 | 0.120 |
Why?
|
Polyurethanes | 1 | 2013 | 4 | 0.120 |
Why?
|
Antigens | 1 | 2013 | 31 | 0.120 |
Why?
|
Chickens | 1 | 2013 | 40 | 0.110 |
Why?
|
Hemostatics | 1 | 2013 | 12 | 0.110 |
Why?
|
Disease Models, Animal | 2 | 2016 | 980 | 0.110 |
Why?
|
Esophageal Diseases | 1 | 2012 | 7 | 0.110 |
Why?
|
Hair | 1 | 2013 | 28 | 0.110 |
Why?
|
Esophagus | 1 | 2012 | 22 | 0.110 |
Why?
|
Aortic Rupture | 1 | 2012 | 7 | 0.110 |
Why?
|
Urinary Bladder | 1 | 2014 | 165 | 0.110 |
Why?
|
Hepatitis C, Chronic | 1 | 2012 | 77 | 0.110 |
Why?
|
Mesenchymal Stem Cells | 1 | 2014 | 161 | 0.110 |
Why?
|
Skin, Artificial | 1 | 2012 | 31 | 0.110 |
Why?
|
Larynx | 1 | 2012 | 19 | 0.110 |
Why?
|
Chondroitin Sulfates | 1 | 2012 | 22 | 0.110 |
Why?
|
Hepatocytes | 1 | 2012 | 74 | 0.110 |
Why?
|
Respiratory Tract Diseases | 1 | 2012 | 30 | 0.110 |
Why?
|
Pancreatic Diseases | 1 | 2012 | 16 | 0.110 |
Why?
|
Aortic Aneurysm, Abdominal | 1 | 2012 | 47 | 0.110 |
Why?
|
Hydrogels | 1 | 2013 | 103 | 0.110 |
Why?
|
Intestinal Diseases | 1 | 2012 | 18 | 0.110 |
Why?
|
Cell Transplantation | 1 | 2012 | 63 | 0.100 |
Why?
|
Blood Vessel Prosthesis | 1 | 2012 | 78 | 0.100 |
Why?
|
Developmental Biology | 1 | 2011 | 7 | 0.100 |
Why?
|
African Americans | 2 | 2016 | 1373 | 0.100 |
Why?
|
Cattle | 1 | 2011 | 100 | 0.100 |
Why?
|
Sarcoidosis | 1 | 2011 | 27 | 0.100 |
Why?
|
Clinical Trials as Topic | 2 | 2012 | 298 | 0.100 |
Why?
|
Biomarkers, Pharmacological | 1 | 2010 | 5 | 0.100 |
Why?
|
Corneal Transplantation | 1 | 2010 | 13 | 0.100 |
Why?
|
Chondrocytes | 1 | 2011 | 71 | 0.100 |
Why?
|
Wound Healing | 1 | 2012 | 182 | 0.100 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2015 | 1079 | 0.100 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2010 | 65 | 0.100 |
Why?
|
Trachea | 1 | 2010 | 55 | 0.090 |
Why?
|
Phenotype | 3 | 2016 | 629 | 0.090 |
Why?
|
Brachiocephalic Veins | 1 | 2009 | 8 | 0.090 |
Why?
|
Cell Survival | 3 | 2017 | 272 | 0.090 |
Why?
|
Incidence | 3 | 2018 | 1119 | 0.090 |
Why?
|
Arteriovenous Fistula | 1 | 2009 | 13 | 0.090 |
Why?
|
Hypersensitivity, Delayed | 1 | 2009 | 5 | 0.090 |
Why?
|
Wounds and Injuries | 1 | 2012 | 250 | 0.090 |
Why?
|
Cell Fractionation | 1 | 2009 | 7 | 0.090 |
Why?
|
Arteriovenous Shunt, Surgical | 1 | 2009 | 45 | 0.080 |
Why?
|
Hand | 1 | 2009 | 63 | 0.080 |
Why?
|
Patient Compliance | 1 | 2010 | 210 | 0.080 |
Why?
|
Retroperitoneal Space | 1 | 2008 | 18 | 0.080 |
Why?
|
Abdominal Pain | 1 | 2008 | 40 | 0.080 |
Why?
|
Thoracic Wall | 1 | 2008 | 6 | 0.080 |
Why?
|
Sex Distribution | 1 | 2008 | 186 | 0.080 |
Why?
|
Age Distribution | 1 | 2008 | 198 | 0.080 |
Why?
|
Anastomosis, Surgical | 1 | 2008 | 49 | 0.080 |
Why?
|
Arteries | 1 | 2008 | 60 | 0.080 |
Why?
|
Diaphragm | 1 | 2008 | 46 | 0.080 |
Why?
|
United States | 4 | 2017 | 3636 | 0.080 |
Why?
|
Neoplasms, Vascular Tissue | 1 | 2007 | 7 | 0.080 |
Why?
|
North Carolina | 3 | 2018 | 1424 | 0.080 |
Why?
|
Rabbits | 3 | 2014 | 185 | 0.080 |
Why?
|
Evidence-Based Medicine | 1 | 2008 | 207 | 0.070 |
Why?
|
Withholding Treatment | 1 | 2006 | 11 | 0.070 |
Why?
|
Creatinine | 3 | 2016 | 174 | 0.070 |
Why?
|
Rats, Nude | 2 | 2017 | 38 | 0.070 |
Why?
|
Heart Failure | 1 | 2012 | 571 | 0.070 |
Why?
|
Pregnancy | 3 | 2015 | 815 | 0.070 |
Why?
|
Rats, Wistar | 2 | 2018 | 84 | 0.070 |
Why?
|
Postoperative Period | 2 | 2017 | 91 | 0.070 |
Why?
|
Triglycerides | 1 | 2007 | 214 | 0.070 |
Why?
|
Models, Animal | 2 | 2017 | 160 | 0.070 |
Why?
|
Hexuronic Acids | 2 | 2017 | 31 | 0.070 |
Why?
|
Glucuronic Acid | 2 | 2017 | 31 | 0.070 |
Why?
|
Cytokines | 2 | 2017 | 243 | 0.070 |
Why?
|
Cohort Studies | 4 | 2012 | 1688 | 0.070 |
Why?
|
Hysterectomy | 1 | 2005 | 37 | 0.070 |
Why?
|
Case-Control Studies | 3 | 2015 | 859 | 0.070 |
Why?
|
Cholesterol | 1 | 2007 | 229 | 0.070 |
Why?
|
Pilot Projects | 2 | 2018 | 473 | 0.070 |
Why?
|
Vena Cava, Inferior | 1 | 2005 | 31 | 0.060 |
Why?
|
Patient Selection | 2 | 2018 | 257 | 0.060 |
Why?
|
Chi-Square Distribution | 2 | 2016 | 293 | 0.060 |
Why?
|
Bile Reflux | 1 | 2004 | 1 | 0.060 |
Why?
|
Anastomosis, Roux-en-Y | 1 | 2004 | 3 | 0.060 |
Why?
|
Reoperation | 2 | 2016 | 203 | 0.060 |
Why?
|
Rats, Inbred Lew | 2 | 2015 | 116 | 0.060 |
Why?
|
Heparitin Sulfate | 1 | 2004 | 1 | 0.060 |
Why?
|
Integrin alphaV | 1 | 2004 | 2 | 0.060 |
Why?
|
Transgenes | 1 | 2004 | 45 | 0.060 |
Why?
|
Severity of Illness Index | 1 | 2007 | 864 | 0.060 |
Why?
|
Odds Ratio | 2 | 2016 | 447 | 0.060 |
Why?
|
Adenoviridae | 1 | 2004 | 61 | 0.060 |
Why?
|
Genetic Vectors | 1 | 2004 | 118 | 0.060 |
Why?
|
Proportional Hazards Models | 2 | 2016 | 709 | 0.060 |
Why?
|
Pregnancy Outcome | 2 | 2015 | 52 | 0.060 |
Why?
|
Immunophenotyping | 2 | 2016 | 49 | 0.060 |
Why?
|
DNA | 2 | 2018 | 204 | 0.060 |
Why?
|
Splenectomy | 1 | 2002 | 19 | 0.050 |
Why?
|
Regression Analysis | 2 | 2017 | 274 | 0.050 |
Why?
|
Liver Function Tests | 2 | 2014 | 19 | 0.050 |
Why?
|
Double-Blind Method | 2 | 2014 | 504 | 0.050 |
Why?
|
Predictive Value of Tests | 2 | 2015 | 787 | 0.050 |
Why?
|
Aged, 80 and over | 2 | 2017 | 3719 | 0.040 |
Why?
|
Adenosine Triphosphate | 1 | 2019 | 52 | 0.040 |
Why?
|
Boston | 1 | 2018 | 16 | 0.040 |
Why?
|
Pluripotent Stem Cells | 1 | 2018 | 18 | 0.040 |
Why?
|
Congresses as Topic | 1 | 2018 | 37 | 0.040 |
Why?
|
Ischemia | 1 | 2019 | 92 | 0.040 |
Why?
|
Fluoroscopy | 1 | 2018 | 37 | 0.040 |
Why?
|
Medical Illustration | 1 | 2018 | 7 | 0.040 |
Why?
|
Leukocytes, Mononuclear | 1 | 2018 | 50 | 0.040 |
Why?
|
Stress, Mechanical | 1 | 2018 | 90 | 0.040 |
Why?
|
Reperfusion | 1 | 2017 | 17 | 0.040 |
Why?
|
Sex Factors | 2 | 2012 | 631 | 0.040 |
Why?
|
Rotation | 1 | 2017 | 46 | 0.040 |
Why?
|
Bone Screws | 1 | 2018 | 56 | 0.040 |
Why?
|
Adipocytes | 1 | 2018 | 79 | 0.040 |
Why?
|
Casts, Surgical | 1 | 2017 | 20 | 0.040 |
Why?
|
Receptors, Cholinergic | 1 | 2017 | 22 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 1 | 2002 | 871 | 0.040 |
Why?
|
Hepacivirus | 2 | 2008 | 37 | 0.040 |
Why?
|
Lumbar Vertebrae | 1 | 2017 | 98 | 0.040 |
Why?
|
Tensile Strength | 1 | 2016 | 52 | 0.040 |
Why?
|
Drug Compounding | 1 | 2017 | 36 | 0.040 |
Why?
|
Fluorescent Antibody Technique | 1 | 2016 | 82 | 0.040 |
Why?
|
Collagen Type I | 1 | 2016 | 39 | 0.040 |
Why?
|
Polyesters | 1 | 2016 | 72 | 0.040 |
Why?
|
Anti-Inflammatory Agents | 1 | 2016 | 90 | 0.030 |
Why?
|
Tetrodotoxin | 1 | 2015 | 10 | 0.030 |
Why?
|
Vasoactive Intestinal Peptide | 1 | 2015 | 3 | 0.030 |
Why?
|
Neurogenesis | 1 | 2015 | 14 | 0.030 |
Why?
|
Gestational Age | 1 | 2015 | 96 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 152 | 0.030 |
Why?
|
Muscle Development | 1 | 2015 | 45 | 0.030 |
Why?
|
Equipment Failure Analysis | 1 | 2015 | 42 | 0.030 |
Why?
|
Preoperative Period | 1 | 2014 | 31 | 0.030 |
Why?
|
Electric Stimulation | 1 | 2015 | 102 | 0.030 |
Why?
|
Muscle Contraction | 1 | 2015 | 114 | 0.030 |
Why?
|
Vasodilation | 1 | 2015 | 87 | 0.030 |
Why?
|
Placebos | 1 | 2014 | 61 | 0.030 |
Why?
|
Genetic Association Studies | 1 | 2015 | 148 | 0.030 |
Why?
|
Haplotypes | 1 | 2015 | 220 | 0.030 |
Why?
|
Prosthesis Design | 1 | 2015 | 87 | 0.030 |
Why?
|
Metaplasia | 1 | 2014 | 20 | 0.030 |
Why?
|
Blood Loss, Surgical | 1 | 2014 | 45 | 0.030 |
Why?
|
Cytomegalovirus Infections | 1 | 2014 | 25 | 0.030 |
Why?
|
Organoids | 1 | 2015 | 68 | 0.030 |
Why?
|
Fibroblast Growth Factor 1 | 1 | 2014 | 9 | 0.030 |
Why?
|
Angiogenesis Inducing Agents | 1 | 2014 | 15 | 0.030 |
Why?
|
Blood Transfusion | 1 | 2014 | 64 | 0.030 |
Why?
|
Actins | 1 | 2014 | 52 | 0.030 |
Why?
|
Myocardium | 1 | 2015 | 170 | 0.030 |
Why?
|
Treatment Failure | 1 | 2014 | 159 | 0.030 |
Why?
|
Multivariate Analysis | 1 | 2016 | 637 | 0.030 |
Why?
|
Genotype | 1 | 2016 | 735 | 0.030 |
Why?
|
Mice, Inbred C57BL | 1 | 2016 | 711 | 0.030 |
Why?
|
Preoperative Care | 1 | 2014 | 110 | 0.030 |
Why?
|
Blood Pressure | 1 | 2018 | 806 | 0.030 |
Why?
|
Chorioallantoic Membrane | 1 | 2013 | 4 | 0.030 |
Why?
|
Fertility | 1 | 2013 | 22 | 0.030 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2013 | 33 | 0.030 |
Why?
|
Chick Embryo | 1 | 2013 | 73 | 0.030 |
Why?
|
Detergents | 1 | 2013 | 17 | 0.030 |
Why?
|
Sus scrofa | 1 | 2013 | 44 | 0.030 |
Why?
|
Length of Stay | 1 | 2014 | 292 | 0.030 |
Why?
|
Colorimetry | 1 | 2013 | 3 | 0.030 |
Why?
|
Cell Cycle | 1 | 2013 | 69 | 0.030 |
Why?
|
Peristalsis | 1 | 2012 | 1 | 0.030 |
Why?
|
Rome | 1 | 2012 | 2 | 0.030 |
Why?
|
Electrophoresis | 1 | 2013 | 7 | 0.030 |
Why?
|
Rheology | 1 | 2013 | 28 | 0.030 |
Why?
|
Extremities | 1 | 2013 | 48 | 0.030 |
Why?
|
Microscopy, Confocal | 1 | 2013 | 62 | 0.030 |
Why?
|
Blood Platelets | 1 | 2013 | 37 | 0.030 |
Why?
|
Hospitals, University | 1 | 2012 | 23 | 0.030 |
Why?
|
Cell Adhesion | 1 | 2013 | 103 | 0.030 |
Why?
|
Capsules | 1 | 2012 | 14 | 0.030 |
Why?
|
Mass Spectrometry | 1 | 2013 | 100 | 0.030 |
Why?
|
Emergencies | 1 | 2012 | 45 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2012 | 246 | 0.030 |
Why?
|
Blotting, Western | 1 | 2013 | 281 | 0.030 |
Why?
|
Sarcoidosis, Pulmonary | 1 | 2011 | 5 | 0.030 |
Why?
|
Blood Glucose | 1 | 2014 | 466 | 0.030 |
Why?
|
Hyperplasia | 1 | 2011 | 38 | 0.030 |
Why?
|
Bile Duct Diseases | 1 | 2011 | 9 | 0.030 |
Why?
|
Adipose Tissue | 1 | 2014 | 327 | 0.020 |
Why?
|
Constriction, Pathologic | 1 | 2011 | 41 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2012 | 641 | 0.020 |
Why?
|
Inflammation | 1 | 2014 | 508 | 0.020 |
Why?
|
European Continental Ancestry Group | 1 | 2015 | 1131 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2011 | 100 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2012 | 747 | 0.020 |
Why?
|
Cholestasis, Intrahepatic | 1 | 2008 | 3 | 0.020 |
Why?
|
Biomedical Engineering | 1 | 2009 | 23 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2011 | 599 | 0.020 |
Why?
|
Receptors, Antigen, T-Cell, gamma-delta | 1 | 2008 | 4 | 0.020 |
Why?
|
Models, Immunological | 1 | 2008 | 10 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2008 | 24 | 0.020 |
Why?
|
DNA, Viral | 1 | 2008 | 39 | 0.020 |
Why?
|
Models, Genetic | 1 | 2008 | 92 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2008 | 155 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2008 | 136 | 0.020 |
Why?
|
Bile | 1 | 2006 | 6 | 0.020 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2006 | 93 | 0.020 |
Why?
|
RNA, Viral | 1 | 2006 | 49 | 0.020 |
Why?
|
Lipids | 1 | 2006 | 210 | 0.020 |
Why?
|
Heparan Sulfate Proteoglycans | 1 | 2004 | 1 | 0.020 |
Why?
|
Immunochemistry | 1 | 2004 | 8 | 0.020 |
Why?
|
beta-Galactosidase | 1 | 2004 | 16 | 0.020 |
Why?
|
Receptors, Peptide | 1 | 2004 | 4 | 0.020 |
Why?
|
Virion | 1 | 2004 | 7 | 0.020 |
Why?
|
Receptors, Immunologic | 1 | 2004 | 18 | 0.020 |
Why?
|
Genes, Reporter | 1 | 2004 | 37 | 0.020 |
Why?
|
Injections, Intramuscular | 1 | 2004 | 42 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2006 | 514 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2004 | 281 | 0.010 |
Why?
|
Muscle, Skeletal | 1 | 2004 | 494 | 0.010 |
Why?
|